Tuberculosis (TB) is caused by infection with
Mycobacterium tuberculosis (M. Tuberculosis, MTB) and despite ongoing global efforts for its eradication there were still an estimated 8.7 million new cases and 1.4 million deaths worldwide in 2011 (1) . Co-infection with HIV caused 13% new actively infected people resulting in a high mortality rate (48.6 %) among these patients (2) . TB is therefore considered as one of the leading causes of death due to infectious diseases worldwide despite the availability of effective and extensive therapeutic approaches (3, 4) . Sarcoidosis is considered an autoimmune disease characterized by multisystem disorder of unclear etiology that involves any organ, but most commonly the lungs and the intrathoracic lymph nodes although the heart, skin and central nervous system are frequently affected (9) . Despite the first clinical description of sarcoidosis over 120 years ago, little is known about the pathogenesis of this disease (10) . A genetic predisposition to sarcoidosis is evident from epidemiological studies of familial aggregation, differences in disease susceptibility and severity between racial groups and the significantly increased incidence of sarcoidosis in monozygotic twins of affected individuals compared to other siblings (11, 12) . More recent results have provided further insights into the genetic risks for However, some TB tissues do not have caseous necrosis and even the distinction between caseation and noncaseation is not absolute. MTB DNA detection in sarcoidosis samples by traditional PCR has been used for the pathological study of sarcoidosis; however, it is likely that real-time RT-qPCR analysis of specific mRNAs and microRNAs will be necessary to provide a sensitive, precise, and rapid diagnostic test for sarcoidosis in TB patients (4) . As a result, there is still no definitive conclusion as to the relationship of MTB with sarcoidosis (31-36).
In conclusion, diagnosing sarcoidosis in patients with a high TB burden poses a significant global challenge. 
